PRNewsWire
17 Dec 2025, 15:11 UTC · 39w ago
Verdict
Headline takes no side. We score RZLT −1.00 — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company's lead drug candidate failed Phase 3 clinical trial endpoints, leading to a sharp stock price decline and a securities investigation.
More negative than 79% of ticker scores this week
The company is mentioned as the subject of a securities class action investigation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Read next
GlobeNewsWire · 13h ago
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
15h ago
+97.0%
Price is moving against the score
$3.98 vs $2.02 close before publication (Dec 16) · not market-adjusted
RZLT chart →
